Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study-Reference-Cited by-同舟云学术

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

Published:2016-09 Issue:9 Volume:27 Page:1725-1732
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Delaloge S.,Pérol D.,Courtinard C.,Brain E.,Asselain B.,Bachelot T.,Debled M.,Dieras V.,Campone M.,Levy C.,Jacot W.,Lorgis V.,Veyret C.,Dalenc F.,Ferrero J.M.,Uwer L.,Kerbrat P.,Goncalves A.,Mouret-Reynier M.A.,Petit T.,Jouannaud C.,Vanlemmens L.,Chenuc G.,Guesmia T.,Robain M.,Cailliot C.

Funder

R&D UNICANCER

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/9/1725/19446793/mdw260.pdf

Reference18 articles.

1. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014

2. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

3. Vascular endothelial growth factor as a target for anticancer therapy;Ferrara;Oncologist,2004